Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study

Eric S. Winer(Providence College), Frédéric Forget, Sebastian Bauer(Science for Life Laboratory), Yasser Mostafa Kamel(Daiichi Sankyo (United States)), Steffen Doerfel(Onkozentrum Dresden), Bogusława Karaszewska(State University of Applied Sciences in Konin), Paul Burgess(Princess Alexandra Hospital), Howard Safran(Brown University), Dilawar Khan(Harbin Clinic), Stacey Kalambakas(Novartis (United States))
International Journal of Hematology
September 1, 2017
10.1007/s12185-017-2319-9
Cited by 67

Related Papers

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k